 The session was widely discussed why there are barriers and which barriers are that limits access to clinical trends in this region of Europe, because it was nicely shown in the report really nicely done by MP, MPI, MPE, that there are running only 6% of clinical trials, but the region of Central and Eastern Europe make up 26% of the population of the European Union. So it's significant, it's definitely an opportunity and a big challenge for this country to improve access to clinical trials, and we have to work on it. It was nicely discussed during the session here in this meeting, and I think that in my presentation I try to show the positive example how it should work in other departments of hematoconcology in other countries. So to me there are, there is clear preconditions which have to be fulfilled otherwise this country or this department can run the clinical trials, and this critical precondition is to establish the clinical trial units. Without clinical trial units currently you can't run clinical trials because clinical trials in especially hematoconcology are very difficult. It's really a lot of work and it can't be done by physicians. You need special data managers, you need research nurse, you need support from hospital, so that's really important to establish clinical trial units. So I will talk about access to the clinical trials from Croatia position, because when we discuss about central Eastern European countries there are really different situations from country to country. For example, Czech Republic and even Poland, they have a lot more of studies than Croatia or Slovenia for example, or Serbia, even Macedonia in Albania they are probably in the worst position. But what we have to say is that Croatia is a small country and we do not have a lot of patients with multiple myeloma, but still we can enroll some patients with clinical trials, but we have a problem that the sponsor actually doesn't offer our number of trials. So if I look back at the last 15 years in Croatia, we have only four trials with multiple myeloma and we actually included a certain number of patients in some more, in some less, but we saw the problem also with the patients, because some patients refused to participate in our study. So we start the collaboration with our patient organizations such as myeloma cro and Croatian leukemia and lymphoma association and start with the educational session in order to try to make our patient more willing to participate because we try to explain them what is the study and why they need to participate. But still we have a problem with some patients because they need to travel to the centers that are doing clinical trials and it is not easy to reach those centers. They need some family members to support them. They also need money to pay someone to bring them to the institution. So there are a lot of problems regarding the patient, but we also have a problem regarding administration because it is too complicated for the sponsors and they need to invest a lot of money to start the clinical trial and then do not have a good number of desirable number of patients. What is also a problem is the management of the hospital because for our as investigators or as researchers, we need to do all the work regarding the clinical trials by myself or my colleagues. We do not have study nurse, our nurse that is doing her regular everyday job need to have an extra time to help us doing some study procedures. So I think that we really need to convenience our management, our hospital management to invest and to build on clinical trials. So it will help us to do that. Doing clinical study will become more easier and not that hard work for the clinicians. And we also have a different problem when we discuss with the sponsors because they really need a long time after submit the paper to the ethics committee and it lasts for six or seven months even to get approval from the ethics committee and then more than one or two months to sign the contracts with the hospital. So it is a really a long time period to activate study centers. That is also a problem. And what you can do to solve those problems is trying to collaborate with the other countries that have a similar problem but it will not help with the sponsors trials because in every country the regulatory, the law is different and the funds will need to get approval from every country. But maybe it can help us to participate in in investigator initiative study, in academic study and that maybe can help us if we collaborate and then in that kind in that way we can have more patients, more number of patients. And also there is a problem about visibility because I think that some of our doctors, our investigators are not actually present in the European community, in European myeloma community and that is also a big problem.